PTC
NPCE icon

Petrus Trust Company’s Neuropace NPCE Stock Holding History

Petrus Trust Company’s Portfolio NPCE Stock Details NPCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-14,384
Closed -$160K – 410
2025
Q2 		$160K Buy
14,384
+927
+7% +$11.6K 0.02% 479
2025
Q1 		$165K Buy
+13,457
New +$168K 0.02% 553
2024
Q2 		– Sell
-23,904
Closed -$316K – 707
2024
Q1 		$316K Buy
+23,904
New +$341K 0.03% 414

Other funds holding NPCE

PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
KLP
Kent Lake PR Anasco, Puerto Rico $198M AUM 5.21% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

Petrus Trust Company's NPCE Position: Q3 2025 in Review

Petrus Trust Company sold out of Neuropace (NPCE) in Q3 2025, closing a stake of 14,384 shares — an estimated $160K sold.

Petrus Trust Company first reported a position in NPCE in Q1 2024 and held it in 3 quarters. The position peaked at $316K in Q1 2024. 80 funds tracked by Wall St. Rank hold NPCE as of Q3 2025.

  • Petrus Trust Company reported no remaining Neuropace position as of Q3 2025 after selling out during the quarter.
  • Petrus Trust Company sold 14,384 Neuropace shares in Q3 2025, an estimated $160K.
  • Petrus Trust Company first reported a position in Neuropace in Q1 2024 and held it in 3 quarters.
  • Petrus Trust Company's Neuropace position peaked at $316K in Q1 2024.
  • 80 funds tracked by Wall St. Rank held Neuropace as of Q3 2025.

Based on Petrus Trust Company's 13F filing for Q3 2025, filed 14 Nov 2025.